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BIOPENANDA KETIDAKSTABILAN PLAK: PERBANDINGAN ANTARA 
SINDROM KORONARI AKUT DAN ANGINA STABIL YANG KRONIK 
ABSTRAK 
 
Biopenanda memainkan peranan yang penting dalam diagnosis dan pengurusan 
penyakit sindrom koronari akut (ACS). Biopenanda seperti, protein C-reaktif (CRP), 
ligan terlarut CD40 (sCD40L), faktor pertumbuhan plasenta (PlGF) dan 
mieloperoksida (MPO) telah dilaporkan terlibat dalam patogenesis penyahstabilan 
plak. Paras biopenanda tersebut dikaji dalam pesakit berumur 45 tahun dan ke bawah 
dan juga mereka yang berumur lebih daripada 45 tahun yang berpenyakit ACS dan 
penyakit angina stabil yang kronik (CSA). Hubungan antara paras biopenanda di 
peredaran koronari dan peredaran periferi juga dikaji bersama. Kajian ini merupakan 
penyelidikan pertama yang menyiasat pengekspresian reseptor pengaktif-proliferasi 
peroksisom (PPARs) dalam pesakit ACS. Sejumlah 79 pesakit (ACS: n = 39, CSA: n 
= 40) terlibat dalam kajian ini. Darah pesakit disampel daripada arteri koronari yang 
tersumbat (peredaran koronari) dan juga daripada vena kubital median (peredaran 
periferi). Paras protein CRP, sCD40L, PlGF dan MPO dalam sampel darah 
ditentukan dengan menggunakan teknik asai imunoerap terangkai enzim (ELISA). 
Paras PPARs intrasel pula diukur dengan menggunakan analisis pemendapan 
Western. Paras mRNA biopenanda tersebut diukur dengan menggunakan analisis 
masa sebenar tindak balas rantai polimerase (real-time PCR). Semua pesakit ACS 
yang menjalani susulan klinikal selama enam bulan dikenalpasti peristiwa mudarat 
kardiak major (MACE) berikutan peristiwa akut. Paras protein CRP, sCD40L, PlGF 
and MPO dalam peredaran periferi didapati meningkat dengan signifikan dalam 
pesakit ACS berbanding dengan pesakit CSA. Tambahan pula, hasil kajian 
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menunjukkan bahawa kepekatan biopenanda tersebut dalam peredaran periferi 
berkait rapat dengan kepekatannya dalam peredaran koronari. Kajian ini juga 
menunjukkan bahawa golongan pesakit berumur di bawah 45 tahun mempunyai 
profil biopenanda yang serupa dengan mereka yang berumur lebih daripada 45 tahun. 
Paras PPAR-γ meningkat dengan signifikan dalam pesakit ACS dan parasnya berkait 
rapat dengan kepekatan sCD40L dan MPO. CRP dalam serum menunjukkan 
keluasan bawah lengkungan yang paling tinggi (0.79, p < 0.001) dalam 
pembezalayan penyakit ACS, diikuti oleh PlGF, MPO dan sCD40L. Tambahan pula, 
biopenanda tersebut juga menunjukkan keupayaan prognostik yang baik untuk 
meramal kejadian MACE dalam masa 30 hari dan enam bulan berikutan serangan 
akut ACS. Kesimpulannya, kajian ini memberi maklumat tambahan mengenai profil 
pengekspresian protein dan gen biopenanda ketidakstabilan plak dalam golongan 
ACS dan CSA. Biopenanda tersebut menyumbang kepada pembentukan plak tidak 
stabil dengan mencetuskan keradangan vaskular, penipisan topi serabut dan 
pembentukan teras lipid yang besar dalam plak koronari. Keupayaan mereka dalam 
membeza layan ACS dan meramal MACE juga menunjukkan keputusan yang 
memberansangkan.  
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PLAQUE INSTABILITY BIOMARKERS: A COMPARISON BETWEEN 
ACUTE CORONARY SYNDROME AND CHRONIC STABLE ANGINA 
PATIENTS 
ABSTRACT 
 
Biomarkers play a pivotal role in the diagnosis and management of patients with 
acute coronary syndrome (ACS). Some biomarkers, such as C-reactive protein (CRP), 
soluble CD40 ligand (sCD40L), placental growth factor (PlGF) and myeloperoxidase 
(MPO) have been reported to be involved in plaque destabilization. The levels of 
these biomarkers were studied in ACS and chronic stable angina (CSA) patients aged 
≤ 45 years and aged > 45 years. The relationship between these biomarkers in the 
coronary circulation and peripheral circulation was also investigated. This study was 
the first attempt to investigate the expression of peroxisome proliferator-activated 
receptors (PPARs) in ACS. A total of 79 patients (ACS: n = 39, CSA: n = 40) was 
recruited. The blood was sampled from the occluded coronary artery (coronary 
circulation) and also from the median cubital vein antecubital fossa (peripheral 
circulation). The serum protein levels of CRP, sCD40L and PlGF and plasma levels 
of MPO were measured using ELISA. The intracellular levels of PPARs were semi-
quantified using Western blot. The mRNA levels of the biomarkers were measured 
by real-time PCR. All ACS patients that underwent six months clinical follow-up 
was assessed for major adverse cardiac events (MACE) after the acute event. The 
peripheral levels of CRP, MPO, sCD40L and PlGF were significantly increased in 
ACS compared to CSA patients. Furthermore, the peripheral concentrations of these 
biomarkers were significantly correlated with the concentrations found in the 
coronary circulation. The patients aged below 45 years and above 45 years shared 
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similar profiles of biomarkers. The expression of PPAR-γ was significantly increased 
in the ACS patients and correlated with both sCD40L and MPO. Serum CRP 
demonstrated the highest area under the curve value of 0.79 (p < 0.001) in 
discriminating ACS, followed by PlGF, MPO and sCD40L. In addition, the 
biomarkers also showed their promising prognostic abilities in predicting 30-day and 
six-month MACE in ACS patients. In conclusion, this study provided additional 
information on the proteins and gene expression profiles of plaque instability 
markers in both CSA and ACS patients. The biomarkers contribute to the formation 
of unstable plaque by triggering vascular inflammation, firous cap thinning and 
formation of large lipid core in coronary plaque. Their accuracies in discriminating 
ACS and predicting MACE also showed promising results.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Introduction of CAD 
1.1.1 Burden of CAD 
Despite dramatic advances in medicine, cardiovascular diseases persist the primary 
cause of death throughout the world and killed nearly 17.5 million people in 2012 
(World Health Organization, 2012a). Of these 17.5 million deaths, an estimated 7.4 
million were caused by coronary heart disease, 6.7 million due to stroke and the 
remaining 3.4 million due to other cardiovascular diseases such as hypertensive heart 
disease, inflammatory heart disease and rheumatic heart disease. According to World 
Health Organization (World Health Organization, 2012b), non-communicable 
diseases caused two-thirds of the total death worldwide in 2012 (Figure 1.1). From 
the total of 38 million deaths caused by non-communicable diseases in 2012, 46% or 
17.5 million deaths were attributed to cardiovascular diseases. 
 
In Malaysia, cardiovascular disease is the leading cause of death of non-
communicable diseases. It caused a quarter of all deaths in Malaysia hospitals in 
2013 (Figure 1.2) (Ministry of Health Malaysia, 2014). According to Ministry of 
Health Hospitals’ Survey reported in year 2002, cardiovascular diseases persistently 
account for 15 to 16% of all hospital deaths annually from 1995 to 2002. 
Furthermore, ischemic heart disease was the primary cause of cardiovascular death 
and was responsible for 12.9% of total deaths in 2008 (Malaysia Department of 
Statistics, 2010). 
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Figure 1.1 The main causes of death worldwide of all ages in year 2012 (World 
Health Organization, 2012b). 
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Total Deaths in 2013 
140 thousands 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 The main causes of death of all ages in Malaysia in year 2013 
(Ministry of Health Malaysia, 2014). 
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1.1.2 Atherosclerosis and CAD 
Synonymous with coronary artery disease (CAD), ischemic heart disease is the most 
common manifestation of myocardial ischemia attributed to critical narrowing (> 75% 
stenosis of the luminal diameter) of any of the three principal epicardial coronary 
arteries, i.e. the left anterior descending artery, left circumflex artery, and the right 
coronary artery. The heart muscle may not receive enough blood supply following 
the luminal narrowing, especially when workloads of the heart increase during 
exercise. This transient ischemia may cause chest pain called angina, which typically 
relieves on rest. The prolonged ischemia eventually leads to irreversible necrosis of 
the muscle cells located distal to the blockage. 
 
In most cases, CAD results from atherosclerosis process. The pathogenesis of 
atherosclerosis has been studied extensively since the last few decades. 
Atherosclerosis is a chronic inflammatory process resulting from the interactions 
between the circulating components (extracellular matrix, plasma lipoproteins, 
leukocytes, platelets) and the arterial wall (Fan and Watanabe, 2003). It involves 
various highly interconnecting processes, including endothelial dysfunction (Topper 
et al., 1996), inflammation (Libby et al., 2002), vascular smooth cell activation (Lee 
et al., 2001), platelets activation (Rauch et al., 2001), altered matrix and lipid 
metabolism (Libby, 1995), thrombosis (Libby and Simon, 2001), remodeling and 
genetic factors (Faxon et al., 2004).  
 
1.1.2.1 History of atherosclerosis research 
The pathogenesis of atherosclerosis was a topic of interest among biological and 
medical scientists in the 18
th
 century. In 1815, a London physician and surgeon 
 5 
 
named Joseph Hodgson reported that inflammation was the underlying cause of 
atherosclerosis, and it occurred in the intima between the lumen and media of the 
diseased coronary vessels (Kaperonis et al., 2006). In 1856, Rudolf Virchow studied 
the pathogenesis of atherosclerosis by investigating the histological characteristics of 
atherosclerotic lesion in all stages (Heidland et al., 2006) and he came out with the 
term “endarteriitis deformans”, that refers to the formation of atheroma within intima 
resulted from inflammation and fibrous thickening attributed to a reactive change in 
intima (Heidland et al., 2006). The report suggested that endarteriitis deformans was 
initiated by mechanical forces and the inflammation acted as a repair mechanism. 
Virchow also suggested in the same year that atherosclerosis occurred when plasma 
components induced an inflammatory response in the arterial wall and resulted in 
local intima injury (Zarifis, 2005). This report emphasizes the local intima injury as 
the earliest stimulus of inflammation. 
 
The clarification on the role of cholesterol in the pathogenesis of atherosclerosis is 
one of the significant discoveries in the 20
th
 century. In 1908, a Russian researcher 
named A.I. Ignatowski, described the relationship between cholesterol-rich food and 
experimental atherosclerosis by feeding rabbits with a diet of milks and eggs. The 
silky smooth lining of arteries of the rabbits turned into yellow cobble stone 
following the cholesterol-rich diet (Konstantinov and Jankovic, 2013). In 1910, 
Adolf Windaus who studied the structure of cholesterol showed that atheromatous 
lesions contained six times higher percentage of free cholesterol and 20 times higher 
amount of esterified cholesterol compared to a normal arterial wall (Konstantinov et 
al., 2006). In 1913, a Russian doctoral student, Nikolai Nikolaevich Anichkov 
showed that cholesterol alone was responsible for the physical changes in the arterial 
 6 
 
walls that led to the subsequent development of coronary or carotid plaque 
(Konstantinov et al., 2006). These discoveries introduced a new era in the 
atherosclerosis research. 
 
In the 20
th
 century, the lipid theory dominated the field of atherogenesis research 
until Russell Ross reopened the discussion on the inflammatory nature of 
atherosclerosis in 1976. Ross, Glomset and Harker produced a response-to-injury 
hypothesis, which suggested that the atherosclerosis lesion is attributed to arterial 
endothelial cell injury (Ross et al., 1977). The endothelial injury is subsequently 
followed by a series of events, including endothelial desquamation, platelets 
adherence and aggregation at the injured sites and intimal smooth muscle 
proliferative response, which are the essential changes prior to the atherosclerotic 
lesion formation (Ross et al., 1977). Moore et. al. (1976) and Bowie et. al. (1975) 
stressed on the vital role of platelets in the promotion of intimal smooth muscle 
proliferation that contributes to the progression of atherosclerosis lesion. The 
response-to-injury hypothesis of atherosclerosis is still valid today with minor 
alterations. The revised response-to-injury hypothesis focused on the endothelial 
dysfunction rather than the endothelial denudation as the trigger of the inflammatory 
response and progression of atherosclerosis (Ross, 1999, Endemann and Schiffrin, 
2004).  
 
1.1.2.2 Progression of atherosclerosis in relation to coronary plaque formation 
Atherosclerosis is a multifactorial and multistep process that usually occurs many 
years before any clinical symptom manifests. According to the response-to-injury 
theory, endothelial dysfunction is the first step in atherosclerosis (Ross et al., 1977) 
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and from this point on, an inflammatory response is triggered that leads to the 
progression of atherosclerotic plaque (Figure 1.3). 
 
Endothelium maintains the normal vascular tone and blood fluidity under normal 
homeostatic conditions. However, endothelial dysfunction can occur in response to a 
variety of stimuli, such as oxidized low-density lipoprotein (LDL), free radicals 
caused by smoking, hypertension, diabetes, genetic alterations, elevated plasma 
homocysteine concentrations and infectious microorganisms (Kaperonis et al., 2006). 
 
Healthy endothelium maintains the non-thrombogenic surface of the vascular system. 
However, activated endothelial cells begin to express adhesion molecules, such as 
selectins, vascular cell adhesion molecules and intercellular adhesion molecules, on 
their surface soon after exposure to atherogenic stimuli. These adhesion molecules 
act as receptors for glycoconjugates and integrins present on monocytes and T-cells 
(Kaperonis et al., 2006). Li et. al. (1993) showed an increased expression of vascular 
cell adhesion molecule-1 on endothelial cells activated by proinflammatory cytokines.  
 
Increased cellular adhesion and associated endothelial dysfunction eventually trigger 
the release of cytokines, recruitment of inflammatory cells and uptake of lipid into 
the atherosclerotic plaque. The vascular cell adhesion molecule-1, intercellular 
adhesion molecule-1 and some of the beta-chemokine receptors assist on the 
adherence of circulating monocytes to the endothelium. Monocytes adhere to the 
endothelium and migrate into the intima with the help of locally activated matrix 
metalloproteinases (MMPs). 
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Figure 1.3 A schematic diagram of processes in the development and progression of atherosclerosis, plaque destabilization and rupture and 
 thrombus formation (Csordas and Bernhard, 2013).  
  Abbreviations: EC: endothelial cell, eNOS: endothelial nitric oxide synthase, NADPH: nicotinamide adenine dinucleotide phosphate, NF- κB: 
  Nuclear factor-κB, ROS: reactive oxygen species, MMP: matrix metalloproteinase.  
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The enzymes aid on the migration of monocytes into the intima through degrading 
the connective tissue matrix (Crowther, 2005). The migrated monocytes 
subsequently differentiate into tissue macrophages in the presence of various 
cytokines such as macrophage colony-stimulating factor (M-CSF), tumor necrosis 
factor alpha (TNF-α), interferon gamma (IFN-γ), proinflammatory interleukins (e.g. 
interleukins-1 and -2; IL-1, -2) and growth factors (such as transforming growth 
factor beta, platelet derived growth factor and insulin-like growth factor-1) (Ross, 
1999).  
 
The M-CSF gives rise to the ingestion of lipids and multiplication and differentiation 
of monocytes into macrophage foam cells. The macrophage foam cell produces 
cytokines and growth factors, further promoting atherosclerosis. It serves as a source 
of MMPs that further promoting the weakening and rupture of the fibrous cap 
(Zandbergen and Plutzky, 2007). The lesion that formed underneath a monolayer of 
endothelial cells, is the first lesion of atherosclerosis and it is named as fatty-streak 
lesion (Kaperonis et al., 2006). 
 
In the fatty-streak lesion, activated T-cells and native vascular wall cells secrete 
cytokines [tumor necrosis factor beta (TNF-β) and IFN-γ)], fibrogenic mediators and 
growth factors that can promote the migration and proliferation of smooth muscle 
cells (Kaperonis et al., 2006). The smooth muscle cells in the intima produce 
extracellular matrix components, including elastin, collagen and proteoglycans, 
which form the fibrous cap and contribute to the stability of the plaque. This fibrous 
cap surrounds a lipid rich core in advanced plaques. The smooth muscle cells also 
synthesize proinflammatory cytokines, including IL-1 and TNF-α. Gradually, an 
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advanced atherosclerotic lesion is formed, with the characteristic of large core of 
lipids and necrotic tissue that is covered with a thin fibrous cap. The atherosclerotic 
lesion that built up in the lining coronary artery is called coronary plaque, which 
blocks blood flow to cardiac muscles. 
 
1.1.3 Coronary plaque composition, morphology and clinical outcome 
1.1.3.1 Stable plaque and CSA 
Coronary plaques can be classified into two types, i.e. white plaques and yellow 
plaques, based on their color and appearance under coronary angioscopy. The white 
plaques have a small lipid core surrounded by thick fibrous cap (Thieme et al., 1996). 
These plaques are rich in collagen, which makes the plaque more stable in structure. 
Most of these lesions grow slowly over several decades in coronary arteries and 
remain clinically silent, or on a long term, may lead to chronic stable angina (CSA) 
(Davies, 1990). 
 
Angina episodes in patients with CSA are typically precipitated by an increase in 
myocardial oxygen demand in the setting of a consistent decrease in blood supply 
due to long-standing and well-developed atherosclerotic white plaques. Coronary 
plaques that contribute to exertional angina symptoms usually obstruct 70% of the 
epicardial coronary vessel lumen. The white plaques in CSA patients are more stable, 
have a reduced lipid pool, and they seldom rupture. Since their geometry does not 
typically change acutely, they provide a relatively fixed reduction in myocardial 
oxygen supply. 
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1.1.3.2 Unstable plaque and ACS 
In comparison to white plaque, the yellow plaques have thinner fibrous caps with 
larger amount of lipids accumulate in the plaque (Thieme et al., 1996). The lipid core 
expands and the thick fibrous cap begins to erode to form a weak fibrous cap, which 
is highly susceptible to rupture (Virmani et al., 2000). Therefore, the yellow plaques 
are always referred as the unstable plaques. The unstable plaque refers to a plaque 
that is likely to rupture and subsequently leads to thrombus formation.  
 
Unstable plaques are responsible for the clinical manifestation of acute coronary 
syndrome (ACS). ST-elevation myocardial infarction (STEMI), non-ST-elevation 
myocardial infarction (NSTEMI) and unstable angina (UA) are a range of clinical 
presentations with a similar underlying pathological mechanism of ACS (Falk, 1985, 
Fuster, 1994). Morphologically, an unstable plaque is characterized by (a) a large 
lipid core (40% of the entire plaque); (b) a thin fibrous cap with thickness less than 
65 mm; (c) with increased macrophage and proteoglycan content; (d) presence of 
calcified nodules (Kolodgie et al., 2001, Virmani et al., 2003).  
 
1.1.3.2 (a) Mechanism of coronary plaque destabilization   
Atherosclerotic plaque undergoes destabilization process to form unstable plaque, 
which is susceptible to rupture and subsequently leads to thrombus formation. 
During atherosclerosis, plaque stability is influenced by the inflammatory cells that 
destabilize the plaque and the reparative function of smooth muscle cells that 
promote plaque stability. Cheng et. al. (1993) hypothesized that the plaque rupture 
occurs following an imbalance between synthesis and breakdown of extracellular 
matrix in the fibrous cap, resulting in depletion of collagen and other matrix 
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components, which in turn leads to cap thinning (Figure 1.4). A thick fibrous cap 
prevents contact between the lipid core and circulating blood. It stabilizes the plaque 
by reducing circumferential tensile stress. In contrast, a thin fibrous cap increases the 
risk of plaque rupture due to its increased tensile stress (Loree et al., 1992). 
 
Vascular smooth muscle cell is the only cell type in the human body that is able to 
synthesize essential extracellular matrix proteins, such as collagen and elastin from 
amino acids. The extracellular matrix is essential in forming the skeleton and 
enhancing stability of the atherosclerotic plaque. Therefore, a decrease in smooth 
muscle cells also results in matrix depletion (Felton et al., 1997, Burleigh et al., 
1992). Inflammatory cells, such as T cells, have been shown to inhibit the matrix 
synthesis by smooth muscle cells. An in vitro study using human smooth muscle cells 
has demonstrated that activated T cells produce IFN-γ, which eventually resulted in 
the down regulation of collagen synthesis by smooth muscle cells (Amento et al., 
1991). 
 
Besides extracellular matrix depletion, the increased in extracellular matrix 
breakdown also attributes to plaque rupture. Macrophages within the fibrous cap can 
be activated by the expression of CD40 ligand on T cells (Phipps, 2000). The 
activated macrophages secrete MMPs, such as collagenases, gelatinases and 
stromelysin that support the breakdown of collagen and elastin to peptides and amino 
acids. The reduction of extracellular matrix content in fibrous cap of a coronary 
plaque thereby increases its likelihood to rupture (Libby, 1995). 
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Figure 1.4 The importance of collagen synthesis and breakdown in the  
 maintenance of the integrity of the fibrous cap (Finn et al., 2010). 
  Abbreviations: IFN-γ: interferon gamma, CD-40L: CD40 ligand, IL-1:  
  interleukin 1, TNF-α: tumor necrosis factor alpha, MCP-1: monocyte  
  chemoattractant protein -1, M-CSF: macrophage colony stimulating factor 
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1.1.3.2 (b) Clinical presentations following plaque destabilization and  
  rupture 
The rupture of an unstable plaque may occur spontaneously or in response to a 
variety of mechanical and hemodynamic forces (MacIsaac et al., 1993, Lee and 
Kamm, 1994). Plaque rupture is defined as a lesion that consists of a necrotic core 
with an overlying thin ruptured fibrous cap, which subsequently leads to luminal 
thrombosis following the interaction between circulating platelets with the 
thrombogenic necrotic core (Virmani et al., 2006). The rupture usually occurs at the 
shoulder regions of the fibrous cap, as this region withstands the highest tensile stress 
and increased MMP production (Galis et al., 1994). Although plaque rupture often 
leads to thrombosis with clinical manifestations of ACS, but it may also occur 
without clinical consequences. 
 
The most common clinical manifestation of plaque rupture is ACS. ACS refers to any 
group of clinical symptoms compatible with acute myocardial ischemia and covers a 
wide spectrum of clinical conditions, ranging from UA to NSTEMI to STEMI 
(Kumar and Cannon, 2009). STEMI is the most severe condition that involves 
complete blockage of coronary artery. As a result, all the surrounding heart muscles 
at the blockage region become ischemic and eventually infarction happens. The 
infarction causes a characteristic elevation in the ST segment on electrocardiogram 
(ECG). The conditions and clinical presentations of UA and NSTEMI are similar, but 
they differ in severity. A diagnosis of NSTEMI can be made when the ischemia is 
sufficiently severe to cause myocardial damage, that results in the release of 
biomarkers of myocardial necrosis into the circulation. The biomarkers include 
muscle and brain fraction of creatine kinase [CK-MB] and cardiac-specific troponins 
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T or I. In contrast, the patient is considered to have experienced UA if there is no 
such biomarker detected in the bloodstream within 12 hours after the initial onset of 
ischemic chest pain. 
 
1.2 Identification of unstable plaque 
The formation of unstable plaque could lead to the occurrence of ACS. Therefore, it 
has been a growing interest in the identification and treatment of unstable plaques 
and unstable patients, which can eventually reduce the mortality and morbidity of the 
disease. During the past decades, enormous efforts have been addressed by scientist 
to identify the unstable plaques using various methods. 
 
1.2.1 Identification of unstable plaque using imaging techniques  
Imaging techniques, such as coronary angiography and echocardiogram, are widely 
used to visualize the coronary arteries. The coronary angiography is an invasive 
imaging test that uses contrast dye and special x-rays to visualize the inner sides of 
coronary arteries. It is the gold standard for the evaluation of coronary plaque. 
However, the unstable plaque is often asymptomatic and it cannot be reliably 
visualized by routine coronary angiography (Cademartiri et al., 2007). To date, there 
is no potential technology that can effectively identify the unstable plaques. However, 
several invasive and non-invasive imaging modalities are currently being developed. 
 
The invasive modalities used to identify unstable plaques include coronary 
intravascular ultrasound (IVUS) and optical coherence tomography (OCT). The 
IVUS views the coronary arteries using a miniaturized ultrasound transducer placed 
at the tip of a catheter (DeMaria et al., 2006). In contrast to coronary angiography 
 16 
 
that can only visualize the vessel lumen, IVUS visualizes both the lumen and the 
vessel wall. Areas of fibrosis and calcification, as well as plaque ruptures or 
ulcerations can also be visualized. Similar to IVUS, the OCT also uses catheter to 
visualize the coronary arteries (Stamper et al., 2006). It uses back reflection of waves 
to characterize arterial wall and plaque structures. However, OCT differs from IVUS 
as it uses infrared light instead of ultrasound.  
 
Besides morphological visualization, the activity of the coronary plaque can be 
reflected in temperature changes. Plaque with high levels of inflammatory activity 
produces heat (Casscells et al., 1996). The heat production could be due to leukocyte 
metabolic activity, ineffective metabolism or increased neoangiogenesis (Madjid et 
al., 2006). Several coronary temperature mapping methods using specialized 
catheters like Volcano catheter and ThermoCoil Guidewire are currently under 
development. These thermo-sensitive catheters measure temperature at the plaque 
and compare the recording to temperature within healthy vascular walls or the 
bloodstream. The“hot spot” detected is hypothesized to represent region prone to 
plaque rupture and local thrombosis.  
 
Besides the temperature difference, arterial walls with unstable plaques have 
different mechanical properties compared to the healthy vascular tissue (Schaar et al., 
2006). Thin fibrous layers, large lipid cores, and inflammatory cells can alter the 
stress-strain relationship of coronary vessels. Intravascular ultrasound palpography is 
developed to assess the mechanical properties of the vascular wall in order to identify 
the unstable plaques. It is a technique that depicts the distribution of the mechanical 
strain over the luminal surface of coronary arteries. It utilizes conventional radio 
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frequency signals to detect the microscopic tissue displacements, which can be 
directly translated into local strain of the vessel wall (de Korte et al., 1998). The local 
strain of the tissue is displayed as a color-coded palpogram on the luminal 
boundaries of IVUS echogram (Doyley et al., 2001). 
 
Magnetic resonance imaging is the most advanced diagnostic modality for cardiac 
structure and function. It is non-invasive and does not utilize nephrotoxic agents as in 
coronary angiography. In addition, the ability of magnetic resonance imaging to 
characterize soft tissue allows it to give a clear picture of various components of the 
atherothrombotic plaque. Magnetic resonance imaging can distinguish between 
adventitial and medial layers, as well as fibrous caps and lipid cores (Wilensky et al., 
2006). Its ability to visualize plaques in the coronary arteries, however, is limited by 
a reduced spatial resolution for deep structures and small size coronary vessels, and 
artefacts due to motion and movement of the patients (Wilensky et al., 2006). 
 
The major drawbacks of these cardiac imaging techniques to be used routinely as a 
point of care test for diagnosis of plaque instability are high cost, time consuming 
and IVUS also carries risk of complications, such as spasm, embolism, thrombus 
formation and dissection (Bourantas et al., 2011). Another limitation of these 
techniques is they are very operator-dependent as they have to be performed by 
trained specialists only (Gani et al., 2007). Besides, the accuracy and precision of 
imaging technique such as magnetic resonance imaging are highly rely on the 
patient’s cooperation, making it not suitable for unstable patients (Shah et al., 2009). 
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1.2.2 Identification of unstable plaque using biomarkers 
The genesis and progression of unstable plaque are accompanied by the release of a 
series of proteomic mediators and these mediators have the potential to be utilized as 
biomarkers. The National Institutes of Health Biomarkers Definitions Working 
Group (2001) defined a biomarker as a characteristic that is objectively measured 
and evaluated as an indicator of normal biological processes, pathogenic processes, 
or pharmacologic responses to a therapeutic intervention. A biomarker can be 
measured on a biological sample (as blood, urine, or tissue test), a recording obtained 
from a person (blood pressure, heart rate or ECG) or it may be an imaging test 
(echocardiogram or computed tomography scan).  
 
According to Biomarkers Definitions Working Group (2001), biomarkers can be 
classified as antecedent biomarkers (identifying the risk of developing an illness), 
screening biomarkers (screening for subclinical disease), diagnostic biomarkers 
(recognizing overt disease), staging biomarkers (categorizing disease severity) or 
prognostic biomarkers (predicting future disease course, including recurrence and 
response to therapy, and monitoring efficacy of therapy). An ideal biomarker has the 
potential to enhance the ability of a clinician to manage the patient optimally. The 
biomarker will be of clinical value only if it is accurate, can be reproduced in a 
standardized fashion, acceptable to the patient, easy to be interpreted by clinicians, 
has high sensitivity and specificity for the outcome. It should also consistently 
explain a reasonable proportion of the outcome independent of established predictors 
(Vasan, 2006). 
 
 19 
 
The major advantage of biomarker over imaging technique in identifying unstable 
plaque is the ease of performing the test on blood sample to detect the presence of a 
biomarker. Another advantage of the use of biomarker is that it is more economical 
and less time consuming compared with the use of imaging techniques. Therefore, 
the detection of biomarkers in blood has been gaining cardiologists’ interest in recent 
years. 
 
Biomarkers play a pivotal role in the diagnosis and management of patients with 
ACS. Early recognition of a cardiac ischemic event and a proper placement of 
patients in the risk spectrum of ACS are crucial in improving the efficiency of 
clinical care of patients. The World Health Organization has traditionally defined 
myocardial infarction as requiring the presence of at least two of three diagnostic 
criteria, namely, (i) the appropriate clinical presentation; (ii) typical changes in the 
ECG; (iii) raised cardiac enzymes, essentially total CK or MB isoform of creatine 
kinase (CK-MB) activities (Panteghini, 2004). Consensus documents published by 
the European Society of Cardiology, the American College of Cardiology, and the 
American Heart Association are to make recommendations on the use of biomarkers 
for the detection of myocardial infarction. The redefined criteria used to classify 
ACS patients presenting with ischemic symptoms as acute, evolving, or recent 
myocardial infarction are heavily predicated on the increased serum or plasma 
cardiac troponin concentration (The Joint European Society of Cardiology/American 
College of Cardiology Committee, 2000).  
 
Troponin is a complex of three contractile regulatory proteins, troponin C, T and I. It 
regulates the interactions between actin and myosin in skeletal and cardiac muscles. 
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Troponin I and T are specific to cardiac muscles while troponin C is expressed in 
both cardiac and skeletal muscles. Thus, troponin C is not appropriate to be used in 
the diagnosis of myocardial damage (Babuin and Jaffe, 2005). Myocardial necrosis 
causes the release of cardiac troponins into circulation. Hence, cardiac troponins, 
mainly cardiac troponin I, become the ideal biomarkers for the detection of cardiac 
injury (Babuin and Jaffe, 2005).  
 
Both cardiac troponin I and cardiac troponin T have similar kinetics. They are 
detectable in the serum within 4 to 12 hours after the onset of myocardial infarction, 
and depending on the duration of ischemia and reperfusion status, the peak values of 
cardiac troponins occur between 12 to 48 hours after symptom onset (Boden et al., 
2008). Therefore, serial sampling, including a baseline sample and follow-up 
examination at 8 to 12 hours after symptom onset is recommended (Newby et al., 
2003). Due to the tissue specificity of cardiac troponins, any reliably detected 
concentration of cardiac troponins in the peripheral circulation is regarded as 
abnormal and indicative of myocardial injury (Jaffe et al., 2000). 
 
Sudden coronary death is the major outcome of ACS and even those who survive 
from it remain at high risk of recurrence. Therefore, despite the success of cardiac 
troponins that can rule out ACS from the emergency room at present, there is still a 
need for the development of early biomarkers that can reliably detect myocardial 
ischemia in the absence of irreversible myocyte injury and thus predict risk for 
developing ACS in asymptomatic patients. There are two categories of biomarkers 
under investigation nowadays, namely markers of early injury or ischemia and 
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markers of inflammation or coronary plaque instability and disruption (Panteghini, 
2004).  
 
1.3 Recommendation on the use of new biomarkers in ACS 
The main etiology of ACS involves rupture of unstable plaque. Several factors such 
as inflammation, impaired endothelial function, impaired plaque stabilization and 
thrombus formation, can lead to plaque instability and a subsequently acute coronary 
event (Libby, 1995, Falk et al., 1995, Davies, 1996, Brown et al., 1993). The 
biomarkers like C-reactive protein (CRP), soluble CD40 ligand (sCD40L), placental 
growth factor (PlGF) and myeloperoxidase (MPO), were chosen as targets in this 
study, due to their significant roles in the pathogenesis of unstable plaque. 
 
1.3.1 CRP and vascular inflammation 
CRP, a biomarker of inflammation, is a valuable predictor of future cardiovascular 
events in apparently healthy men and women (Ridker et al., 2001, Ridker, 2003). 
The CRP could directly participate in the pathogenesis of atherosclerosis through the 
activation of endothelial cells (Calabro et al., 2003).  
 
CRP, named for its capacity to bind to the C-polysaccharide of Streptococcus 
pneumoniae, was the first acute-phase protein described in Yeh and Palusinski 
(2003). It is synthesized by the hepatocytes in response to microbial infection, tissue 
injury, and autoimmune disorders. It had been shown that Interleukin-1 beta (IL-1β) 
and IL-6 actively induced the expression of CRP in human hepatocytes and 
hepatoma cells (Calabro et al., 2003). Human neuronal cells were found to produce 
CRP in Alzheimer’s disease (Yasojima et al., 2000). In addition, human renal 
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cortical tubular epithelial cells were shown to produce CRP after inflammatory 
stimulation (Jabs et al., 2003). Interestingly, CRP has been detected in human 
atherosclerotic plaques and it could be resulted from indirect deposition of 
circulating cells or direct production by cells in the arterial wall (Yasojima et al., 
2001). Furthermore, it was demonstrated to be secreted by other cell types such as 
smooth muscle cells (Calabro et al., 2003), macrophages (Ciubotaru et al., 2005), 
and endothelial cells (Venugopal et al., 2005). 
 
The exact function of CRP is unclear. However, it is thought to stimulate tissue 
factor production and activate complement when aggregated (Volanakis, 1982). 
Tissue factor may be the main stimulus for initiating blood coagulation. An in vitro 
study have shown that aggregated CRP binds to LDL and very-LDL, which in turn 
activates complement, stimulates tissue factor production by macrophages and 
eventually initiates blood coagulation cascade (de Ferranti and Rifai, 2002).  
 
Another theory sees CRP as a culprit in atherogenesis. It acts as pro-coagulant and 
increases opsonization (Tracy, 1998). CRP in the presence of serum mediates the 
uptake of LDL into macrophages, which then become foam cells (Zwaka et al., 
2001). It also destabilizes plaques (Lagrand et al., 1999). Furthermore, CRP is 
hypothesized as a marker of vascular inflammation. This hypothesis is supported by 
the finding of decreased forearm vascular responsiveness in patients with increased 
CRP (Fichtlscherer et al., 2000). Then, a work has contributed further to the theory 
of CRP as a marker of vascular inflammation. Pasceri et al. (Pasceri et al., 2000) 
found that CRP caused an increase in the expression of intercellular adhesion 
molecule-1, vascular cell adhesion molecule-1 and E-selectin, and promotes local 
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infiltration by monocytes and lymphocytes. Further, Yoo and colleagues (2011) 
measured vascular inflammation in their study using F-fluorodeoxyglucose positron 
emission tomography. They found that the vascular inflammation increased in 
healthy individuals without hyperlipidemia but with elevated CRP. 
 
1.3.2 sCD40L and platelets activation 
CD40 is a cell membrane-spanning protein of 50 kDa that is found originally on B 
lymphocytes. Its ligand, CD40 ligand (CD40L) or termed as CD 154, is a trimeric 
transmembrane protein with a molecular mass of 36 kDa. CD40L is expressed in 
hematopoietic cell types such as T lymphocytes, monocytes, or platelets and 
nonhematopoietic cells such as endothelial and smooth muscle cells (Mach et al., 
1997b, Foy et al., 1996).  
 
Ligation of CD40 on various vascular cells plays a role in the pathogenesis of 
atherosclerosis, thrombosis, and inflammatory processes (Henn et al., 1998, Mach et 
al., 1998). The engagement of CD40 on endothelial cells or monocytes leads to the 
synthesis of reactive oxygen species, production of chemokine and cytokine as well 
as the expression of adhesion molecules, such as E-selectin, intercellular adhesion 
molecule 1 and vascular cell adhesion molecule 1, which further promotes the 
recruitment of leukocytes and enhances atherogenesis. 
 
Beside present in the form of membrane bound protein, the CD40L is also present in 
soluble form, termed as sCD40L (Graf et al., 1995). This biologically active sCD40L 
is shed from stimulated lymphocytes and released into circulation following platelets 
stimulation (Lee et al., 1999, Henn et al., 2001). It triggers inflammatory response in 
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vascular endothelial cells by secretion of cytokines and chemokines (Andre et al., 
2002). sCD40L is also able to inhibit the endothelial cell migration (Urbich et al., 
2002), activate platelets aggregation (Chakrabarti et al., 2005) and enhance the 
monocyte tissue factor expression and thrombin generation (Sanguigni et al., 2005). 
 
Membrane bound CD40L and sCD40L interact with the CD40 receptor molecules, 
which are located not only on B cells but also on monocytes, macrophages, 
endothelial and smooth muscle cells in atheroma. The interaction leads to release of 
matrix MMPs and subsequently plaque destabilization (Schonbeck and Libby, 2001). 
The CD40/CD40L interactions also play an important role in thrombotic events after 
plaque rupture. The CD40/CD40L interactions induce tissue factor expression on 
macrophages and endothelial cells as well as diminish the expression of 
thrombomodulin, which favoring coagulation and thrombosis (Aukrust et al., 2004). 
Gavins and colleagues (2010) showed that the CD40-CD40L system significantly 
enhanced microvascular thrombosis in both mouse models of chronic and acute 
inflammation.  
 
1.3.3 PlGF and inflammatory instigation  
PlGF is a member of the vascular endothelial growth factor family, encoding for a 
50-kDa angiogenic protein with approximately 50% identical to vascular endothelial 
growth factor in the platelet-derived growth factor–like domain (Maglione et al., 
1991). The PlGF was initially discovered in the placenta and it has been proposed to 
control the growth and differentiation of trophoblasts (Khaliq et al., 1996). Besides 
the placenta, PlGF is also expressed in the heart, lungs, goiter and thyroid tissues 
